Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
2011

Study of Everolimus in Chinese Patients with Advanced Solid Tumors

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): Xu BingHe, Wu YiLong, Shen Lin, Ye DingWei, Jappe Annette, Cherfi Azzeddine, Wang Hui, Yuan RuiRong

Primary Institution: Cancer Hospital Chinese Academy of Medical Sciences

Hypothesis

Everolimus will be safe and effective in Chinese patients with advanced solid tumors.

Conclusion

Everolimus 5 or 10 mg/day was well tolerated in Chinese patients with advanced solid tumors.

Supporting Evidence

  • Everolimus was absorbed rapidly with median Tmax of 3 hours for 5 mg and 2 hours for 10 mg.
  • The most common adverse events were increased blood glucose and fatigue.
  • Best tumor response was stable disease in 83% of patients on 5 mg and 50% on 10 mg.

Takeaway

This study tested a medicine called everolimus in Chinese patients with serious cancers to see if it was safe and worked well.

Methodology

24 patients were randomized to receive either 5 mg or 10 mg of everolimus daily, and their safety and pharmacokinetics were assessed.

Limitations

The study had a small sample size and was limited to specific cancer types.

Participant Demographics

Patients included 12 with breast cancer, 6 with gastric cancer, 6 with non-small cell lung cancer, and 6 with renal cell carcinoma.

Statistical Information

Confidence Interval

95% CI for stable disease duration was 2.89-8.05 months for 5 mg/day and 3.58-not reached for 10 mg/day.

Digital Object Identifier (DOI)

10.1186/1756-8722-4-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication